ProShare Advisors’s Cogent Biosciences COGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.08M Sell
28,006
-4,039
-13% -$149K ﹤0.01% 777
2025
Q4
$1.14M Buy
32,045
+4,842
+18% +$136K ﹤0.01% 791
2025
Q3
$391K Buy
27,203
+1,182
+5% +$14K ﹤0.01% 1252
2025
Q2
$187K Buy
26,021
+1,020
+4% +$5.66K ﹤0.01% 1739
2025
Q1
$150K Sell
25,001
-6,073
-20% -$47.6K ﹤0.01% 1760
2024
Q4
$242K Buy
31,074
+7,267
+31% +$72.4K ﹤0.01% 1786
2024
Q3
$257K Buy
23,807
+6,779
+40% +$66K ﹤0.01% 1571
2024
Q2
$144K Sell
17,028
-5,178
-23% -$39.3K ﹤0.01% 1601
2024
Q1
$149K Buy
22,206
+2,953
+15% +$18.3K ﹤0.01% 1746
2023
Q4
$113K Buy
19,253
+3,130
+19% +$24K ﹤0.01% 1761
2023
Q3
$157K Buy
16,123
+2,565
+19% +$30.4K ﹤0.01% 1538
2023
Q2
$161K Buy
13,558
+1,179
+10% +$13.5K ﹤0.01% 1594
2023
Q1
$134K Sell
12,379
-1,639
-12% -$21K ﹤0.01% 1534
2022
Q4
$162K Buy
14,018
+1,430
+11% +$17.7K ﹤0.01% 1547
2022
Q3
$188K Buy
+12,588
New +$173K ﹤0.01% 1425
2022
Q2
Sell
-11,101
Closed -$83K 1850
2022
Q1
$83K Sell
11,101
-2,633
-19% -$18.3K ﹤0.01% 2064
2021
Q4
$118K Buy
+13,734
New +$119K ﹤0.01% 2170
2019
Q3
Sell
-2,708
Closed -$28K 1663
2019
Q2
$28K Sell
2,708
-362
-12% -$4.82K ﹤0.01% 1597
2019
Q1
$54K Buy
3,070
+32
+1% +$547 ﹤0.01% 1611
2018
Q4
$53K Buy
+3,038
New +$89.9K ﹤0.01% 1521

Other funds holding COGT

ProShare Advisors's COGT Position: Q1 2026 in Review

ProShare Advisors reduced its Cogent Biosciences (COGT) stake by 13% in Q1 2026, selling an estimated $149K and leaving 28,006 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #777.

ProShare Advisors first reported a position in COGT in Q4 2018 and has held it in 20 quarters since. The position peaked at $1.14M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • ProShare Advisors held 28,006 shares of Cogent Biosciences worth $1.08M as of Q1 2026.
  • ProShare Advisors sold 4,039 Cogent Biosciences shares in Q1 2026, an estimated $149K.
  • Cogent Biosciences made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #777 holding.
  • ProShare Advisors first reported a position in Cogent Biosciences in Q4 2018 and has held it in 20 quarters since.
  • ProShare Advisors's Cogent Biosciences position peaked at $1.14M in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.